Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

被引：0

作者：

Fox, Christopher P. ^{[1
]}

Townsend, William ^{[2
]}

Gribben, John G. ^{[3
]}

Menne, Tobias ^{[4
]}

Kalakonda, Nagesh ^{[5
]}

Williams, Paula ^{[6
]}

Toron, Farah ^{[6
]}

Tyas, Emma ^{[7
]}

Cooper, Miranda ^{[7
]}

Rickards, Joshua ^{[7
]}

Radford, John ^{[8
,9
]}

机构：

[1] Univ Nottingham, Sch Med, Nottingham, England

[2] Univ Coll London Hosp, NHS Fdn Trust, London, England

[3] Barts Hlth NHS Trust, Barts Canc Inst, London, England

[4] Newcastle Tyne Hosp, NHS Fdn Trust, Newcastle Upon Tyne, England

[5] Univ Liverpool, Mol & Clin Canc Med, Liverpool, England

[6] Bristol Myers Squibb, Uxbridge, England

[7] Lumanity, Farnham, England

[8] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England

[9] Univ Manchester, Manchester, England

来源：

EJHAEM | 2024年 / 5卷 / 05期

关键词：

ASCT; LBCL; outcomes; real-world evidence; TRANSPLANTATION;

D O I：

10.1002/jha2.970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

引用

页码：992 / 997

页数：6

共 50 条

[1] Real-world practice patterns and outcomes in Veterans with relapsed/refractory diffuse large B-cell lymphoma
Chien, Hsu-Chih
Morreall, Deborah
Patil, Vikas
Rasmussen, Kelli M.
Li, Chungyang
Yong, Christina M.
Burningham, Zachary
Masaquel, Anthony
Halloran, Mary
De Long-Sieg, Elisha
Schulz, Mathias
Sauer, Brian C.
Halwani, Ahmad S.
FUTURE ONCOLOGY, 2020, 17 (04) : 411 - 422
[2] Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphoma
Gatwood, Justin
Masaquel, Anthony
Fox, David
Sheinson, Daniel
James, Cameron
Li, Jia
Hossain, Farah
Ross, Ryan
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 738 - 745
[3] Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Nastoupil, Loretta J.
Andersen, Clark R.
Ayers, Amy
Wang, Yucai
Habermann, Thomas M.
Chihara, Dai
Kahl, Brad S.
Link, Brian K.
Koff, Jean L.
Cohen, Jonathon B.
Martin, Peter
Lossos, Izidore S.
Stanchina, Michele
Haddadi, Sara
Casulo, Carla
Ayyappan, Sabarish
Lin, Ruitao
Li, Ziyi
Larson, Melissa A.
Maurer, Matthew J.
Huynh, Lynn
Gao, Chi
Ramasubramanian, Ramya
Duh, Mei Sheng
Mutebi, Alex
Wang, Tongsheng
Jun, Monika
Wang, Anthony
Kamalakar, Rajesh
Kalsekar, Anupama
Cerhan, James R.
Flowers, Christopher R.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (04) : e183 - e199.e8
[4] Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma
Crombie, Jennifer L.
Jun, Monika
Wang, Tongsheng
Mutebi, Alex
Wang, Anthony
Chhibber, Anindit
Kamalakar, Rajesh
Ukropec, Jon
Blaedel, Julie
Kalsekar, Anupama
LEUKEMIA & LYMPHOMA, 2024, 65 (11) : 1623 - 1633
[5] Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma
Iacoboni, Gloria
Villacampa, Guillermo
Martinez-Cibrian, Nuria
Bailen, Rebeca
Lopez Corral, Lucia
Sanchez, Jose M.
Guerreiro, Manuel
Carolina Caballero, Ana
Mussetti, Alberto
Sancho, Juan-Manuel
Hernani, Rafael
Abrisqueta, Pau
Solano, Carlos
Sureda, Anna
Briones, Javier
Martin Garcia-Sancho, Alejandro
Kwon, Mi
Luis Reguera-Ortega, Juan
Barba, Pere
CANCER MEDICINE, 2021, 10 (10): : 3214 - 3223
[6] Real World Outcomes in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Receiving Palliative Intent Therapies
Ayers, Emily C.
Margolis, David
Landsburg, Daniel J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (10) : 661 - 667
[7] Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis
Riedell, Peter A.
Grady, Connor B.
Nastoupil, Loretta J.
Luna, Alejandro
Ahmed, Nausheen
Maziarz, Richard T.
Hu, Marie
Brower, Jamie
Hwang, Wei-Ting
Schuster, Stephen J.
Chen, Andy I.
Oluwole, Olalekan O.
Bachanova, Veronika
Mcgurik, Joseph P.
Perales, Miguel-Angel
Bishop, Michael R.
Porter, David L.
BLOOD ADVANCES, 2025, 9 (05) : 1232 - 1241
[8] Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L.
Miklos, D. B.
Jacobson, C. A.
Perales, M-A
Kersten, M-J
Oluwole, O. O.
Ghobadi, A.
Rapoport, A. P.
McGuirk, J.
Pagel, J. M.
Munoz, J.
Farooq, U.
van Meerten, T.
Reagan, P. M.
Sureda, A.
Flinn, I. W.
Vandenberghe, P.
Song, K. W.
Dickinson, M.
Minnema, M. C.
Riedell, P. A.
Leslie, L. A.
Chaganti, S.
Yang, Y.
Filosto, S.
Shah, J.
Schupp, M.
To, C.
Cheng, P.
Gordon, L., I
Westin, J. R.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (07) : 640 - 654
[9] Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma
Kambhampati, Swetha
Saumoy, Monica
Schneider, Yecheskel
Serrao, Steve
Solaimani, Pejman
Budde, Lihua Elizabeth
Mei, Matthew G.
Popplewell, Leslie L.
Siddiqi, Tanya
Zain, Jasmine
Forman, Stephen J.
Kwak, Larry W.
Rosen, Steven T.
Danilov, V. Alexey
Herrera, Alex F.
Thiruvengadam, Nikhil R.
BLOOD, 2022, 140 (19) : 2024 - 2036
[10] Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in England
Moore, Sally
Cornic, Laura
Crossman-Barnes, Christina-Jane
Jose, Sophie
Khalaf, Zeyad
Yong, Kwee
Soutar, Megan
Woods, Philip
EJHAEM, 2025, 6 (01):

← 1 2 3 4 5 →